DOCSLIB.ORG

Efficacy of a New Once-Daily Long-Acting Inhaled B2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy of a New Once-Daily Long-Acting Inhaled B2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD Chronic obstructive pulmonary disease Efficacy of a new once-daily long-acting inhaled Thorax: first published as 10.1136/thx.2009.125435 on 3 June 2010. Downloaded from b2-agonist indacaterol versus twice-daily formoterol in COPD Ronald Dahl,1 Kian Fan Chung,2 Roland Buhl,3 Helgo Magnussen,4 Vladimir Nonikov,5 Damon Jack,6 Patricia Bleasdale,6 Roger Owen,6 Mark Higgins,6 Benjamin Kramer,7 on behalf of the INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators < b Supplementary figures/tables ABSTRACT include the twice-daily inhaled 2-agonists formo- are published online only. To Background Indacaterol is a long-acting inhaled b2- terol and salmeterol. It may be hypothesised that view these files please visit the agonist (LABA) for the treatment of chronic obstructive the sustained bronchodilation provided by a bron- journal online (http://thorax.bmj. com). pulmonary disease (COPD). In previous studies, chodilator with a 24 h duration would reduce indacaterol provided 24 h bronchodilation on once-daily fluctuations in airway patency compared with 1Department of Respiratory Diseases, Aarhus University dosing with a fast onset of action. This study compared twice-daily bronchodilators, and may improve Hospital, Aarhus, Denmark the efficacy and safety of indacaterol with the twice- clinical outcomes. 2 b Airway Disease, National Heart daily LABA formoterol and placebo over 1 year. Indacaterol is a novel inhaled long-acting 2- and Lung Institute, Imperial Methods Patients with moderate to severe COPD were agonist providing 24 h bronchodilation on once- College and Royal Brompton e randomised to receive once-daily indacaterol 300 mg daily dosing.2 4 This 1-year study was designed to Hospital, London, UK ¼ m ¼ fi 3Pulmonary Department, Mainz (n 437) or 600 g(n 428), twice-daily formoterol provide ef cacy and long-term safety information University Hospital, Mainz, 12 mg(n¼435) or placebo (n¼432) for 52 weeks in on indacaterol compared with placebo and formo- Germany a double-blind double-dummy parallel group study. The 4 terol. Our primary hypothesis was that indacaterol Pulmonary Research Institute primary efficacy variable was forced expiratory volume in would have a greater effect than placebo on forced at Hospital Grosshansdorf, Center for Pneumology and 1 s (FEV1) measured 24 h postdose after 12 weeks expiratory volume in 1 s (FEV1) at 24 h post-dose Thoracic Surgery, (indacaterol vs placebo). Other outcomes included (‘trough’) after 12 weeks. Grosshansdorf, Germany dyspnoea (transition dyspnoea index, TDI), use of as- 5Central Clinical Hospital, needed salbutamol, symptom-based measures recorded Moscow, Russia METHODS 6 on diary cards, exacerbations, health status (St George’s Novartis Horsham Research Patients http://thorax.bmj.com/ Respiratory Questionnaire), BODE index (body mass Centre, Horsham, West Sussex, Subjects aged $40 years with a clinical diagnosis of UK index, obstruction, dyspnoea, exercise), safety and 5 7 moderate to severe COPD and a smoking history of Respiratory Development, tolerability. $ Novartis Pharmaceuticals 20 pack-years, with postbronchodilator (salbu- Results Indacaterol increased 24 h postdose FEV1 after m < $ Corporation, East Hanover, New tamol 400 g) FEV1 80% and 30% predicted and 12 weeks by 170 ml (both doses) versus placebo and by Jersey, USA ratio of FEV to forced vital capacity (FVC) <70% 100 ml versus formoterol (all p<0.001). These 1 were enrolled in the study. Factors preventing study Correspondence to significant differences were maintained at 52 weeks. entry included respiratory tract infection or hospi- Professor R Dahl, Department of Symptomatic outcomes were improved compared with on September 26, 2021 by guest. Protected copyright. talisation for COPD exacerbation within the Respiratory Diseases, Aarhus placebo with all active treatments, and indacaterol was University Hospital, Aarhus, previous 6 weeks, oral corticosteroids or change in more effective than formoterol in improving TDI score Denmark; [email protected] ICS during the previous month, or history of asthma. and reducing the need for as-needed salbutamol. Received 19 August 2009 Indacaterol was well tolerated and had a good overall Study design Accepted 23 March 2010 safety profile, including minimal impact on QTc interval b A 2-week run-in was followed by 52 weeks of and systemic 2-mediated events. double-blind treatment (see figure S1 in online Conclusions Once-daily indacaterol is an effective 24 h supplement), with patients randomised to treat- bronchodilator that improves symptoms and health ment (1:1:1:1) with stratification for smoking status and confers clinical improvements over a twice- status (current/ex-smoker) using an automated daily 12 h LABA as a treatment for patients with interactive system. Data were collected from moderate to severe COPD. outpatient clinics and physicians’ offices. Trial registration number NCT 00393458. The study treatments were indacaterol 300 mg and 600 mg delivered once daily via single-dose dry powder inhaler (SDDPI), formoterol 12 mg twice Current management guidelines for chronic daily (the standard therapeutic dose) via its obstructive pulmonary disease (COPD) provide proprietary SDDPI and matching placebos to a clear treatment algorithm for the maintenance indacaterol and formoterol taken each morning treatment of COPD, recommending initial treat- (08:00e10:00; both devices) and evening ment with one or more long-acting bronchodilators (20:00e22:00; proprietary SDDPI only). Fixed-dose b for patients with moderate, severe and very severe combinations of ICS plus long-acting 2-agonist disease, with the addition of inhaled corticosteroids were replaced by monotherapy ICS at an equivalent (ICS) for patients who exacerbate frequently.1 The dose and regimen plus salbutamol as-needed. long-acting bronchodilators currently available Patients on ICS monotherapy continued treatment Thorax 2010;65:473e479. doi:10.1136/thx.2009.125435 473 Chronic obstructive pulmonary disease at a stable dose throughout the study. Patients were given same model (with appropriate covariates) was used to analyse Thorax: first published as 10.1136/thx.2009.125435 on 3 June 2010. Downloaded from salbutamol to use as-needed but were asked not to take it within other efficacy variables. The results are presented as estimated 6 h before each visit. Other bronchodilators or corticosteroids adjusted treatment effects (least squares means) and treatment were not allowed unless to treat a COPD exacerbation. Partici- contrasts with 95% CIs and two-sided p values. For trough FEV1 pating physicians were responsible for treating exacerbations. at weeks 12 and 52, SGRQ total score, TDI score and daily salbutamol use, missing values were replaced using last obser- Assessments vation carried forward. Data were carried forward for Patients visited the clinics on days 1, 2, 15, 29, 84, 85, 113, 168, a maximum of 11 weeks, and for trough FEV1 no data were 197, 253, 364 and 365. The visits on days 1 and 2, week 12 and carried forward from before day 15. Exploratory analyses of week 52 were on consecutive days in order to provide a precise week 12 trough FEV1 values were performed in subgroups fi trough FEV1 value which was based on the mean of two de ned according to baseline age, disease severity, smoking measurements taken 23 h 10 min and 23 h 45 min following the history or ICS use. A hierarchical testing procedure to control previous day’s morning dose. At other visits the 15 min predose type I error for multiplicity was used for the comparisons of value was used as a ‘trough’ measurement. In a subset of indacaterol and placebo for the primary end point, then in turn patients, spirometry was performed serially over 24 h postdose. for days of poor COPD control, SGRQ total score at week 12 Patients were given a diary to record peak expiratory flow (PEF), and time to first COPD exacerbation. Other analyses were not symptoms, use of salbutamol, any change in concomitant adjusted for multiplicity. medications and adverse events. Time to first COPD exacerbation was analysed using a Cox COPD exacerbations were defined as onset or worsening of regression model with the assumption of proportional hazards more than one respiratory symptom (dyspnoea, cough, sputum checked with Schoenfeld residuals of treatment effects plotted purulence or volume or wheeze) for >3 consecutive days (based against time. The number of COPD exacerbations over 52 weeks on diary cards or patients’ reports of their health since the was analysed using a Poisson regression model with a sensitivity previous visit) plus documented proof of intensified treatment analysis to assess the impact of premature discontinuations by (eg, systemic steroids, antibiotics or oxygen) and/or hospital- imputing an additional one exacerbation for these patients. isation or emergency room visit. Neither the Cox nor the Poisson regression model assumes Health status (St George’s Respiratory Questionnaire, normality. Normal distribution was assumed for efficacy and SGRQ)6 and dyspnoea (baseline and transition dyspnoea indices, safety variables where ANCOVAs were performed. For the BDI/TDI7) were measured on day 1 and weeks 4, 8, 12, 24, 44 primary and important secondary variables (excluding exacer- and 52. The modified Medical Research Council (mMRC) bations), the normality assumption was checked with a quant- dyspnoea scale89was measured on day 1, week 12 and week 52 ileequantile plot of residuals for each treatment group. followed by the 6-min
Load more

Recommended publications
  • 1 Effect of Indacaterol, a Novel Long-Acting Beta 2
    ERJ Express. Published on November 29, 2006 as doi: 10.1183/09031936.00032806 EFFECT OF INDACATEROL, A NOVEL LONG-ACTING BETA 2-AGONIST, ON HUMAN ISOLATED BRONCHI Emmanuel Naline (1), Alexandre Trifilieff (2), Robin A. Fairhurst (2), Charles Advenier (1), Mathieu Molimard (3) (1) Research Unit EA220, Université de Versailles, Faculté de Médecine, Pharmacology, Hôpital Foch, 40 rue Worth, 92150 Suresnes, France (2) Novartis Institute for BioMedical Research, Horsham, England (3) Département de Pharmacologie, Université Victor Segalen Bordeaux 2; CHU Pellegrin; INSERM U657, Bordeaux, France Correspondence: Mathieu Molimard Département de Pharmacologie CHU de Bordeaux - Université Victor Segalen-INSERM U657 33076 Bordeaux cedex, France Phone: 33 (0)5 57 57 15 60 Fax: 33 (0)5 57 57 46 71 E-mail: [email protected] Short title: Indacaterol effect on isolated human bronchi 1 Copyright 2006 by the European Respiratory Society. Abstract Indacaterol is a novel β2-adrenoceptor agonist in development for the once-daily treatment of asthma and COPD. This study evaluated the relaxant effect of indacaterol on isolated human bronchi obtained from lungs of patients undergoing surgery for lung carcinoma. Potency (-logEC50), intrinsic efficacy (Emax) and onset of action were determined at resting tone. Duration of action was determined against cholinergic neural contraction induced by electrical field stimulation (EFS). At resting tone, -logEC50 and Emax values were, respectively, 8.82±0.41 and 77±5% for indacaterol, 9.84±0.22 and 94±1% for formoterol, 8.36±0.16 and 74±4% for salmeterol, and 8.43±0.22 and 84±4% for salbutamol. In contrast to salmeterol, indacaterol did not antagonize the isoprenaline response.
    [Show full text]
  • Trimbow, INN-Beclometasone / Formoterol / Glycopyrronium Bromide
    23 May 2017 EMA/CHMP/290028/2017 – Rev 1 Committee for Medicinal Products for Human Use (CHMP) Summary of opinion1 (initial authorisation) Trimbow beclometasone / formoterol / glycopyrronium bromide On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Trimbow, intended for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The applicant for this medicinal product is Chiesi Farmaceutici S.p.A., Italy. Trimbow is a triple combination of an inhaled glucocorticoid (beclometasone dipropionate), a long-acting beta2 receptor agonist (formoterol fumarate dihydrate) and a long-acting muscarinic antagonist (glycopyrronium bromide). It will be available as a pressurised metered dose inhaler delivering a solution with a nominal dose per actuation of 87 micrograms / 5 micrograms / 9 micrograms of the active substances respectively. Beclometasone reduces inflammation in the lungs, whereas formoterol and glycopyrronium produce relaxation of bronchial smooth muscle helping to dilate the airways and make breathing easier (ATC code: R03AL09). The benefits with Trimbow are its ability to relieve and prevent symptoms such as shortness of breath, wheezing and cough and to reduce exacerbations of COPD symptoms. The most common side effects of Trimbow are oral candidiasis, muscle spasm and dry mouth. The full indication is: “Maintenance treatment in adult patients with moderate to severe
    [Show full text]
  • 22518Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22518Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) 7 CLINICAL PHARMACOLOGY REVIEW NDA: 22-518 Brand Name: Dulera Generic Name: Mometosone furoate / formoterol fumarate Indication: Asthma (b) (4) in adults and children 12 years of age and older Dosage Form: Inhalation aerosol Strengths: (b) (4) 100/5, 200/5 mcg Route of Administration: Oral Inhalation Dosing regimen: Two inhalations twice daily (morning and evening) Applicant: Schering-Plough and Novartis OCP Division: DCP2 Clinical Division: DPAP (OND-570) Submission Date: May 21, 2009 Reviewers: Ying Fan, Ph.D., Liang Zhao, Ph.D. Team Leader (Acting): Partha Roy, Ph. D. TABLE OF CONTENTS 1 EXECUTIVE SUMMARY.................................................................................................... 3 1.1 Recommendations ........................................................................................................................3 1.2 Phase IV commitments.................................................................................................................3 1.3 Summary of Clinical Pharmacology and Biopharmaceutics findings.....................................3 2 QUESTION BASED REVIEW............................................................................................. 9 2.1 General Attributes/Background..................................................................................................9 2.1.1 What is the pertinent regulatory background of DULERA? .....................................
    [Show full text]
  • Medicaid Policy Change
    MEDICAID POLICY CHANGE IMMINENT PERIL JUSTIFICATION September 25, 2019 ADVAIR: POLICY CHANGE: LDH is changing the preferred drug list to switch the diskus inhaled powder from preferred to non-preferred and adding the HFA inhaler to the preferred list instead. JUSTIFICATION: This product is used to control symptoms and prevent complications caused by asthma or chronic obstructive pulmonary disease. This change is necessary to make an easier delivery device available for recipients to aid with treatment. Without preferred status, recipients would be required to obtain prior authorization which could delay necessary treatment. This change is needed by 10/1/19 due to the coming seasonal change in weather, including influenza and allergy season, that can significantly exacerbate chronic lung diseases, and so this presents an imminent peril to public health. EFFECTIVE DATE: October 1, 2019 LA Medicaid Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL) Effective Date: July 15October 1, 2019 AG – Authorized Generic DR – Concurrent Prescriptions Must Be Written by Same Prescriber PU – Prior Use of Other Medication is Required AL – Age Limits DS – Maximum Days’ Supply Allowed QL – Quantity Limits BH – Behavioral Health Clinical Authorization Required for Children Younger Than 6 DT – Duration of Therapy Limit RX – Specific Prescription Requirements Years Old BY – Diagnosis Codes Bypass Some Requirements DX – Diagnosis Code Requirements TD – Therapeutic Duplication UN – Drug Use Not Warranted (Needs Appropriate CL – More Detailed Clinical Information
    [Show full text]
  • Beclometasone / Formoterol / Glycopyrronium Bromide Pressurised Metered Dose Inhaler (Trimbow®) for the Treatment of COPD
    Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) for the treatment of COPD Commissioning Statement Fylde and Wyre Clinical Commissioning Group has agreed to fund the prescribing of Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) for the treatment of COPD Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy This medicine is classified as GREEN (Restricted) for this indication Summary of supporting evidence TRILOGY shows that in patients with COPD who have severe or very severe airflow limitation,symptoms, and an exacerbation history, triple therapy with BDP/FF/GB (beclomethasone dipropionate / formoterol fumarate / glycopyrronium bromide) had a greater effect on pre-dose and 2-h post-dose FEV1 than BDP/FF. For the co-primary endpoint measuring breathlessness (Transition Dyspnea Index, TDI), superiority of BDP/FF/GB over BDP/FF was not shown. The rate of moderate-to-severe COPD exacerbations was 23% lower with BDP/FF/GB compared with BDP/FF, with the time to first exacerbation significantly longer with triple therapy. Thus, the greater improvement in lung function with BDP/FF/GB compared with BDP/FF was more clearly accompanied by a reduction in exacerbations than an improvement in breathlessness in this group of patients. Furthermore, BDP/FF/GB had a greater effect on health related quality of life than BDP/FF. TRINITY met the primary and both key secondary endpoints. Extrafine fixed triple (i.e. extra fine inhaled particle fraction, ICS/LABA/LAMA in one inhaler) resulted in a 20% (95% CI 8– 31) reduction in the rate of moderate-to-severe COPD exacerbations compared with tiotropium, together with a 0·061L mean improvement in pre-dose FEV1.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME TRELEGY ELLIPTA 100/62.5/25 fluticasone furoate (100 micrograms)/umeclidinium (as bromide) (62.5 micrograms)/vilanterol (as trifenatate) (25 micrograms), powder for inhalation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 92 micrograms fluticasone furoate, 55 micrograms umeclidinium (equivalent to 65 micrograms umeclidinium [as bromide]) and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 62.5 micrograms umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide) and 25 micrograms vilanterol (as trifenatate). Excipient with known effect: Each delivered dose contains approximately 25 milligrams of lactose (as monohydrate). For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for inhalation. White powder in a light grey inhaler (Ellipta) with a beige mouthpiece cover and a dose counter. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications TRELEGY ELLIPTA is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with a long- acting muscarinic receptor antagonist (LAMA) + long-acting beta2-receptor agonist (LABA) + inhaled corticosteroid (ICS). TRELEGY ELLIPTA should not be used for the initiation of COPD treatment. 4.2. Dose and method of administration Patients can be changed from their existing inhalers to TRELEGY ELLIPTA at the next dose. However it is important that patients do not take other LABA or LAMA or ICS while taking TRELEGY ELLIPTA. A stepwise approach to the management of COPD is recommended, including the cessation of smoking and a pulmonary rehabilitation program.
    [Show full text]
  • Arformoterol Tartrate) Inhalation Solution 3 15 Mcg*/2 Ml 4 *Potency Expressed As Arformoterol 5 6 for Oral Inhalation Only 7 8 WARNING: ASTHMA RELATED DEATH
    ® 1 BROVANA 2 (arformoterol tartrate) Inhalation Solution 3 15 mcg*/2 mL 4 *potency expressed as arformoterol 5 6 For oral inhalation only 7 8 WARNING: ASTHMA RELATED DEATH 9 Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related 10 death. Data from a large placebo-controlled US study that compared the safety of 11 another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual 12 asthma therapy showed an increase in asthma-related deaths in patients receiving 13 salmeterol. This finding with salmeterol is considered a class effect of LABA, 14 including arformoterol, the active ingredient in BROVANA (see WARNINGS). The 15 safety and efficacy of BROVANA in patients with asthma have not been established. 16 All LABA, including BROVANA, are contraindicated in patients with asthma 17 without use of a long-term asthma control medication (see 18 CONTRAINDICATIONS). 19 20 DESCRIPTION 21 BROVANA (arformoterol tartrate) Inhalation Solution is a sterile, clear, colorless, 22 aqueous solution of the tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol. 23 Arformoterol is a selective beta2-adrenergic bronchodilator. The chemical name for 24 arformoterol tartrate is formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2­ 25 (4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3­ 26 dihydroxybutanedioate (1:1 salt), and its established structural formula is as follows: OH H N . HO OH CH3 HO OCH3 HOOC COOH HN H 27 O 28 The molecular weight of arformoterol tartrate is 494.5 g/mol, and its empirical formula ٠C4H6O6 (1:1 salt).
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • Asthma Medications
    Relievers / Rescue / Bronchodilators Asthma Short-acting Beta Agonists 2 Medications Ipratropium Bromide ProAir ProAir RespiClick Proventil Ventolin Xopenex albuterol sulfate albuterol sulfate dry powder albuterol sulfate albuterol sulfate levalbuterol tartrate 90mcg 90mcg 90mcg 90mcg 45mcg Teva Teva Merck GlaxoSmithKline Sunovion Atrovent* Combivent Respimat* ipratropium bromide ipratropium bromide 20mcg, 17mcg albuterol sulfate 100mcg Boehringer Ingelheim Boehringer Ingelheim Nebulized Albuterol Xopenex Inhalation Solution Xopenex Inhalation Solution Xopenex Inhalation Solution * Ipratropium bromide is not a recommended rescue inhaler albuterol sulfate levalbuterol HCl levalbuterol HCl levalbuterol HCl outside of use in the emergency room or urgent care but may, 2.5mg/3mL 0.31mg/3mL 0.63mg/3mL 1.25mg/3mL on occasion, be prescribed to supplement short-acting Beta 2 generic Sunovion Sunovion Sunovion agonists. Controllers Inhaled Corticosteroids (ICS): Metered-Dose Inhalers (MDI) Aerospan Alvesco Alvesco Asmanex Asmanex Flovent Flovent Flovent flunisolide ciclesonide ciclesonide mometasone furoate mometasone furoate fluticasone propionate fluticasone fluticasone propionate 80mcg 80mcg 160mcg 100mcg 200mcg 44mcg propionate 220mcg Meda Pharmaceuticals Sunovion Sunovion Merck Merck GlaxoSmithKline 110mcg GlaxoSmithKline GlaxoSmithKline Inhaled Corticosteroids (ICS): Dry Powder Inhalers(continued on back) QVAR QVAR beclomethasone beclomethasone dipropionate dipropionate 40mcg 80mcg ArmonAir RespiClick ArmonAir RespiClick ArmonAir RespiClick
    [Show full text]
  • HIM.PA.153 Inhaled Agents for Asthma and COPD
    Clinical Policy: Inhaled Agents for Asthma and COPD Reference Number: HIM.PA.153 Effective Date: 03.01.21 Last Review Date: 02.21 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are inhaled agents for asthma and/or chronic obstructive pulmonary disease (COPD) requiring prior authorization: • Short acting beta-2 agonist (SABA): albuterol (ProAir® Digihaler®), levalbuterol (Xopenex® HFA, Xopenex® inhalation solution) • Inhaled corticosteroid (ICS): budesonide (Pulmicort Respules®)*, ciclesonide (Alvesco®), fluticasone (Armonair® Digihaler™), mometasone (Asmanex® HFA, Asmanex® Twisthaler®) • Long acting beta-2 agonist (LABA): arformoterol (Brovana®), formoterol (Perforormist) • Long acting muscarinic antagonist (LAMA): aclidinium bromide (Tudorza® Pressair®), glycopyrrolate (Seebri™ Neohaler®, Lonhala® Magnair®), revefenacin (Yupelri®) • Combination ICS/LABA: budesonide/formoterol (Symbicort®)*, fluticasone/salmeterol (Advair Diskus®*, AirDuo® Digihaler™, AirDuo® RespiClick®), mometasone/formoterol (Dulera®) • Combination LABA/LAMA: aclidnium/formoterol (Duaklir® Pressair®), indacaterol/glycopyrrolate (Utibron™ Neohaler®), tiotropium/olodaterol (Stiolto® Respimat®) • Combination ICS/LAMA/LABA: budesonide/glycopyrrolate/formoterol (Breztri Aerosphere™) _______________ *Generic agents do not require prior authorization. FDA Approved Indication(s) ProAir Digihaler and Xopenex are indicated for the treatment or prevention of bronchospasm
    [Show full text]